[go: up one dir, main page]

EA201000612A1 - Антагонисты cgrp-пептиды - Google Patents

Антагонисты cgrp-пептиды

Info

Publication number
EA201000612A1
EA201000612A1 EA201000612A EA201000612A EA201000612A1 EA 201000612 A1 EA201000612 A1 EA 201000612A1 EA 201000612 A EA201000612 A EA 201000612A EA 201000612 A EA201000612 A EA 201000612A EA 201000612 A1 EA201000612 A1 EA 201000612A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salts
peptides
hydrates
antagonists
cgrp
Prior art date
Application number
EA201000612A
Other languages
English (en)
Inventor
Дирк Готтшлинг
Георг Даманн
Хенри Додс
Аннекатрин Хайманн
Штефан Георг Мюллер
Клаус Рудольф
Герхард Шэнцле
Дирк Штенкамп
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201000612A1 publication Critical patent/EA201000612A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описаны новые антагонисты CGRP-пептида общей формулы (I)в которой U, V, X, Y, R, Rи Rимеют указанные в описании и в формуле изобретения значения, их таутомеры, их изомеры, их диастереомеры, их энантиомеры, их гидраты, их смеси и их соли, а также гидраты солей, прежде всего их физиологически совместимые соли с неорганическими или органическими кислотами, содержащие эти соединения лекарственные средства, их применение и способ их приготовления.
EA201000612A 2007-10-18 2008-10-16 Антагонисты cgrp-пептиды EA201000612A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118811 2007-10-18
PCT/EP2008/063967 WO2009050234A1 (de) 2007-10-18 2008-10-16 Cgrp-antagonisten

Publications (1)

Publication Number Publication Date
EA201000612A1 true EA201000612A1 (ru) 2010-10-29

Family

ID=39047647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000612A EA201000612A1 (ru) 2007-10-18 2008-10-16 Антагонисты cgrp-пептиды

Country Status (17)

Country Link
US (1) US8450327B2 (ru)
EP (2) EP2386558B1 (ru)
JP (1) JP5366960B2 (ru)
KR (1) KR20100091972A (ru)
CN (1) CN101827845A (ru)
AU (1) AU2008313733A1 (ru)
BR (1) BRPI0817835A2 (ru)
CA (1) CA2702503A1 (ru)
CO (1) CO6270226A2 (ru)
EA (1) EA201000612A1 (ru)
EC (1) ECSP10010105A (ru)
IL (1) IL204928A0 (ru)
MA (1) MA31782B1 (ru)
MX (1) MX2010003849A (ru)
NZ (1) NZ585347A (ru)
TN (1) TN2010000173A1 (ru)
WO (1) WO2009050234A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
JP5366960B2 (ja) 2007-10-18 2013-12-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｇｒｐアンタゴニスト
WO2009065919A2 (de) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organische verbindungen
JP5603409B2 (ja) * 2010-03-12 2014-10-08 日本曹達株式会社 ｔ−ブトキシカルボニルアミン化合物の製造方法
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
SG10202110874TA (en) 2016-06-07 2021-11-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
LT3601239T (lt) 2017-03-23 2024-10-10 Jacobio Pharmaceuticals Co., Ltd. Nauji heterocikliniai dariniai, naudingi kaip shp2 inhibitoriai
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
EP4188375A4 (en) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited MIGRAINE TREATMENT
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ507292A (en) 1998-04-10 2003-12-19 G Heterocyclic glycyl beta-alanine derivatives useful as vitronectin antagonists
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2002022592A2 (en) 2000-09-14 2002-03-21 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
US6831087B2 (en) 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
US20040063735A1 (en) 2002-06-05 2004-04-01 Chaturvedula Prasad V. Calcitonin gene related peptide receptor antagonists
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1697342A2 (en) 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018795A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
JP2008512460A (ja) 2004-09-08 2008-04-24 メルク エンド カムパニー インコーポレーテッド 単環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬
CA2580020A1 (en) * 2004-09-09 2006-03-23 Ian M. Bell Aryl spirolactam cgrp receptor antagonists
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
JP5426878B2 (ja) 2005-05-24 2014-02-26 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ−結合カセットトランスポーターのモジュレーター
AU2006263962A1 (en) 2005-06-29 2007-01-04 Palau Pharma, S.A. Bicyclic derivatives as p38 kinase inhibitors
DE102005050892A1 (de) 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CA2650932C (en) 2006-05-09 2013-01-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
WO2008070014A2 (en) 2006-12-04 2008-06-12 Neurogen Corporation Biaryl ketone-substituted piperidines
WO2009034029A2 (de) 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
JP5366960B2 (ja) 2007-10-18 2013-12-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｇｒｐアンタゴニスト
WO2009065919A2 (de) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organische verbindungen
JP2011504481A (ja) 2007-11-22 2011-02-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen

Also Published As

Publication number Publication date
US20110172218A1 (en) 2011-07-14
MA31782B1 (fr) 2010-10-01
US8450327B2 (en) 2013-05-28
ECSP10010105A (es) 2010-06-29
MX2010003849A (es) 2010-04-27
IL204928A0 (en) 2010-11-30
CA2702503A1 (en) 2009-04-23
EP2205599A1 (de) 2010-07-14
AU2008313733A1 (en) 2009-04-23
EP2205599B1 (de) 2012-06-06
NZ585347A (en) 2011-09-30
KR20100091972A (ko) 2010-08-19
TN2010000173A1 (fr) 2011-11-11
JP2011500637A (ja) 2011-01-06
CN101827845A (zh) 2010-09-08
BRPI0817835A2 (pt) 2015-03-31
EP2386558A1 (de) 2011-11-16
WO2009050234A1 (de) 2009-04-23
CO6270226A2 (es) 2011-04-20
JP5366960B2 (ja) 2013-12-11
EP2386558B1 (de) 2014-10-01

Similar Documents

Publication Publication Date Title
EA201000612A1 (ru) Антагонисты cgrp-пептиды
EA200802210A1 (ru) Замещенные пролинамиды, их получение и их применение в качестве лекарственных средств
EA200601621A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
WO2009065919A3 (de) Organische verbindungen
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201100037A1 (ru) Органические соединения
EA201170772A1 (ru) Органические соединения
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
EA200500601A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
EA201201167A1 (ru) Соединения в качестве антагонистов брадикинина b1
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
EA200500600A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200970156A1 (ru) Пиридизиноновые производные
EA200800439A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
ECSP109953A (es) Derivados de piridazinona
EA200702620A1 (ru) ЗАМЕЩЕННЫЕ ГЛИЦИНАМИДЫ С АНТИТРОМБОТИЧЕСКИМ И ИНГИБИРУЮЩИМ ФАКТОР Xa ДЕЙСТВИЕМ
EA200870409A1 (ru) Антагонисты киназы pi3
BRPI0923728A2 (pt) "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase".
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
EA200601459A1 (ru) НОВЫЕ АМИДЫ КАРБОНОВЫХ КИСЛОТ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения